CNTB Stock Analysis: Buy, Sell, or Hold?
CNTB - Connect Biopharma Holdings Limited Ordinary Shares
$2.36
0.08 (3.51%)
â˛
5d:
-7.45%
30d:
+7.27%
90d:
+0.0%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When CNTB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CNTB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CNTB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CNTB is currently trading at $2.36, which is considered slightly high relative to its 30-day fair value range of $2.08 to $2.40.
Technical Outlook: Technically, CNTB is in a downtrend. Immediate support is located at $2.11, while resistance sits at $2.64. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: CNTB scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.25 (+207.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CNTB is in a downtrend. Immediate support is located at $2.11, while resistance sits at $2.64. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: CNTB scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.25 (+207.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.08 -
$2.40
Company Quality Score
40/100
(SELL)
Options IV Signal
37th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
52.1%
All Signals
- NEUTRAL: Options fairly priced (IV 37th percentile)
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 207.2% below Wall St target ($7.25)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.08 -
$2.40
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$0.63
(26.6%)
Support & Resistance Levels
Support Level
$2.11
Resistance Level
$2.64
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.64
Wall Street Target
$7.25
(+207.2%)
Revenue Growth (YoY)
5666.7%
Share & Embed Analysis
Last updated: August 24, 2026 4:35 AM ET
Data refreshes hourly during market hours. Next update: 5:35 AM
Data refreshes hourly during market hours. Next update: 5:35 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNTB showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
James Huang
BUY
1160000 shares
2026-03-31
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$560 | 30 SELL |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
